

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 605(TM) anti-human CD4

RRID:AB_2564391

Type: Antibody

Proper Citation

BioLegend Cat# 300556, RRID:AB_2564391

Antibody Information

URL: http://antibodyregistry.org/AB_2564391

Proper Citation: BioLegend Cat# 300556, RRID:AB_2564391

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2564391

Vendor: BioLegend

Catalog Number: 300556

Alternative Catalog Numbers: 300555

Record Creation Time: 20250820T044158+0000

Record Last Update: 20250820T194132+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wang Y, et al. (2026) AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma. Cell metabolism, 38(8), 1702.

Reiné J, et al. (2026) Host-microbial interactions at the nasal mucosa in young children and adults: A retrospective, cross-sectional study. Cell reports, 45(5), 117346.

Martínez-Balboa Y, et al. (2025) Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. iScience, 28(8), 113167.

Mathews JA, et al. (2024) Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF- γ 1 and IL-2 confer immunoregulatory functions to NK cells. iScience, 27(12), 111416.

Du X, et al. (2024) Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis. The Journal of clinical endocrinology and metabolism, 109(11), 2823.

Li S, et al. (2023) Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell reports, 42(3), 112241.

Koutsakos M, et al. (2023) SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity, 56(4), 879.

Anderson W, et al. (2023) PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses. eLife, 12.

Koutsakos M, et al. (2022) The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 55(7), 1316.

Schnizer C, et al. (2022) Persistent humoral and CD4+ TH cell immunity after mild SARS-CoV-2 infection-The CoNAN long-term study. Frontiers in immunology, 13, 1095129.

Andreas N, et al. (2022) Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. Vaccines, 10(1).

Li W, et al. (2020) Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. *Immunity*, 53(2), 456.

de Mingo Pulido Á, et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. *Cancer cell*, 33(1), 60.